Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
This is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Exclude pregnancy and discontinue hormonal contraceptives prior to this initiation. Orally one tablet once daily. In case of missed dose, need to take as soon as possible the same day and then resume regular dosing the next day at the usual time. If concomitant use of oral P-gp inhibitors is unavoidable, need to take this tablet at least 6 hours before taking the P-gp inhibitor.Safety and effectiveness of in pediatric patients have not been established.
Side Effects
Most common adverse reactions (incidence >3%) are: Hot flush, Hyperhidrosis or night sweats, Uterine bleeding, Alopecia, Decreased libido.
Cautions & Contraindications
Warnings & Precautions
Thromboembolic disorders and vascular events: Discontinue this tablet, if an arterial or venous thrombotic, cardiovascular or cerebrovascular event occurs. Bone Loss: Decreases in Bone Mineral Density (BMD) that may not be completely reversible. Depression, mood disorders and suicidal ideation: Advise patients to seek medical attention for new onset or worsening depression, anxiety or other mood changes. Risk of early pregnancy loss: Can cause early pregnancy loss. Advise women to use effective non-hormonal contraception.
Contraindications
High risk of arterial, venous thrombotic or thromboembolic disorder. Pregnancy. Known osteoporosis. Current or history of breast cancer or other hormone sensitive malignancies. Known hepatic impairment or disease. Undiagnosed abnormal uterine bleeding. Known hypersensitivity to relugolix, estradiol or norethindrone acetate.